With only 8 capsules, PENTASA 500 mg delivers 4 grams of mesalamine throughout the small and large intestine

  • Patients who are noncompliant with their 5-ASA therapy have more than a five fold greater risk of flaring than compliant patients.8
  • PENTASA 500-mg capsules deliver 4 grams of mesalamine with 50% fewer capsules vs. the 250-mg formulation.

Next: Efficacy

PENTASA 500-mg capsules deliver 4 grams of mesalamine in only 8 capsules

Capsules are not actual size.

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.